Corcept Therapeutics Inc (CORT)
22.48
-0.52
(-2.26%)
USD |
NASDAQ |
Apr 24, 16:00
22.50
+0.02
(+0.11%)
Pre-Market: 20:00
Corcept Therapeutics Net Income (Quarterly): 31.36M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 31.36M |
| September 30, 2023 | 31.38M |
| June 30, 2023 | 27.53M |
| March 31, 2023 | 15.88M |
| December 31, 2022 | 16.60M |
| September 30, 2022 | 34.61M |
| June 30, 2022 | 27.41M |
| March 31, 2022 | 22.80M |
| December 31, 2021 | 32.05M |
| September 30, 2021 | 30.47M |
| June 30, 2021 | 26.52M |
| March 31, 2021 | 23.46M |
| December 31, 2020 | 25.99M |
| September 30, 2020 | 21.62M |
| June 30, 2020 | 28.33M |
| March 31, 2020 | 30.06M |
| December 31, 2019 | 29.38M |
| September 30, 2019 | 26.34M |
| June 30, 2019 | 20.19M |
| March 31, 2019 | 18.27M |
| December 31, 2018 | 22.01M |
| September 30, 2018 | 17.75M |
| June 30, 2018 | 18.20M |
| March 31, 2018 | 17.46M |
| December 31, 2017 | 98.33M |
| Date | Value |
|---|---|
| September 30, 2017 | 13.76M |
| June 30, 2017 | 12.65M |
| March 31, 2017 | 4.388M |
| December 31, 2016 | 4.597M |
| September 30, 2016 | 2.585M |
| June 30, 2016 | 0.977M |
| March 31, 2016 | -0.019M |
| December 31, 2015 | 0.959M |
| September 30, 2015 | -0.601M |
| June 30, 2015 | -1.936M |
| March 31, 2015 | -4.83M |
| December 31, 2014 | -3.895M |
| September 30, 2014 | -6.006M |
| June 30, 2014 | -7.552M |
| March 31, 2014 | -13.93M |
| December 31, 2013 | -11.12M |
| September 30, 2013 | -10.91M |
| June 30, 2013 | -11.90M |
| March 31, 2013 | -12.08M |
| December 31, 2012 | -11.12M |
| September 30, 2012 | -8.293M |
| June 30, 2012 | -7.597M |
| March 31, 2012 | -11.03M |
| December 31, 2011 | -9.936M |
| September 30, 2011 | -6.435M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
15.88M
Minimum
Mar 2023
34.61M
Maximum
Sep 2022
26.42M
Average
27.41M
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| Ultragenyx Pharmaceutical Inc | -123.19M |
| Alnylam Pharmaceuticals Inc | -137.87M |
| Catalyst Pharmaceuticals Inc | 34.84M |
| United Therapeutics Corp | 217.10M |
| XOMA Corp | -20.11M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 135.40M |
| Total Expenses (Quarterly) | 103.74M |
| EPS Diluted (Quarterly) | 0.28 |
| Enterprise Value | 1.959B |
| Gross Profit Margin (Quarterly) | 98.61% |
| Profit Margin (Quarterly) | 23.16% |
| Earnings Yield | 4.23% |
| Operating Earnings Yield | 4.27% |
| Normalized Earnings Yield | 4.226 |